Anders Møller Greve

Anders Møller Greve

Auto-generated profile, based on publicly available information

Anders Møller Greve

Department of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AGAnders M. Greve
Anders M. Greve
CBCasper N. Bang
Casper N. Bang
KBKurt Boman
Kurt Boman
KEKenneth Egstrup
Kenneth Egstrup
JFJulie Forman
Julie Forman
KWKristian Wachtell
Kristian Wachtell

2 December 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
CBCasper N. Bang
Casper N. Bang
AGAnders M. Greve
Anders M. Greve
ARAnne B. Rossebø
Anne B. Rossebø
SRSimon Ray
Simon Ray
KEKenneth Egstrup
Kenneth Egstrup
KWKristian Wachtell
Kristian Wachtell
Background: Patients with aortic stenosis ( AS ) often have concomitant hypertension. Antihypertensive treatment with a β‐blocker (Bbl) is frequently avoided because of fear of depression of left ventricular function. However, it remains unclear whether antihypertensive treatment with a Bbl is associated with increased risk of cardiovascular events in patients with asymptomatic mild to moderate AS . Methods and Results: We did a post hoc analysis of 1873 asymptomatic patients with mild to moderate AS and preserved left ventricular ejection fraction in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study. Propensity‐matched Cox regression and competing risk analyses were used to assess risk ratios for all‐cause mortality, sudden cardiac death, and cardiovascular death. A total of 932 (50%) patients received Bbl at baseline. During a median follow‐up of 4.3±0.9 years, 545 underwent aortic valve replacement, and 205 died; of those, 101 were cardiovascular deaths, including 40 sudden cardiovascular deaths. In adjusted analyses, Bbl use was associated with lower risk of all‐cause mortality (hazard ratio 0.5, 95% confidence interval 0.3‐0.7, P <0.001), cardiovascular death (hazard ratio 0.4, 95% confidence interval 0.2‐0.7, P <0.001), and sudden cardiac death (hazard ratio 0.2, 95% confidence interval 0.1‐0.6, P =0.004). This was confirmed in competing risk analyses (all P <0.004). No interaction was detected with AS severity (all P >0.1). Conclusions: In post hoc analyses Bbl therapy did not increase the risk of all‐cause mortality, sudden cardiac death, or cardiovascular death in patients with asymptomatic mild to moderate AS . A prospective study may be warranted to determine if Bbl therapy is in fact beneficial. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00092677.

1 August 2011 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AGAnders M. Greve
Anders M. Greve
EGEva Gerdts
Eva Gerdts
KBKurt Boman
Kurt Boman
CGChrista Gohlke-Baerwolf
Christa Gohlke-Baerwolf
ARAnne B. Rossebø
Anne B. Rossebø
KWKristian Wachtell
Kristian Wachtell

1 July 2014 in Stroke
Verified
Journal Article
Open access
AGAnders M. Greve
Anders M. Greve
MDMorten Dalsgaard
Morten Dalsgaard
CBCasper N. Bang
Casper N. Bang
KEKenneth Egstrup
Kenneth Egstrup
SRSimon Ray
Simon Ray
KWKristian Wachtell
Kristian Wachtell
Background and Purpose—: There are limited data on risk stratification of stroke in aortic stenosis. This study examined predictors of stroke in aortic stenosis, the prognostic implications of stroke, and how aortic valve replacement (AVR) with or without concomitant coronary artery bypass grafting influenced the predicted outcomes. Methods—: Patients with mild-to-moderate aortic stenosis enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Diabetes mellitus, known atherosclerotic disease, and oral anticoagulation were exclusion criteria. Ischemic stroke was the primary end point, and poststroke survival a secondary outcome. Cox models treating AVR as a time-varying covariate were adjusted for atrial fibrillation and congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years and female sex (CHA 2 DS 2 -VASc) scores. Results—: One thousand five hundred nine patients were followed for 4.3±0.8 years (6529 patient-years). Rates of stroke were 5.6 versus 21.8 per 1000 patient-years pre- and post-AVR; 429 (28%) underwent AVR and 139 (9%) died. Atrial fibrillation (hazard ratio [HR], 2.7; 95% confidence interval [CI], 1.1–6.6), CHA 2 DS 2 -VASc score (HR 1.4 per unit; 95% CI, 1.1–1.8), diastolic blood pressure (HR, 1.4 per 10 mm Hg; 95% CI, 1.1–1.8), and AVR with concomitant coronary artery bypass grafting (HR, 3.2; 95% CI, 1.4–7.2, all P ≤0.026) were independently associated with stroke. Incident stroke predicted death (HR, 8.1; 95% CI, 4.7–14.0; P <0.001). Conclusions—: In patients with aortic stenosis not prescribed oral anticoagulation, atrial fibrillation, AVR with concomitant coronary artery bypass grafting, and CHA 2 DS 2 -VASc score were the major predictors of stroke. Incident stroke was strongly associated with mortality. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00092677.

1 December 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AGAnders M. Greve
Anders M. Greve
CBCasper N. Bang
Casper N. Bang
KBKurt Boman
Kurt Boman
KEKenneth Egstrup
Kenneth Egstrup
YKY. Antero Kesäniemi
Y. Antero Kesäniemi
KWKristian Wachtell
Kristian Wachtell

1 February 2018 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
ATAllison D. Ta
Allison D. Ta
Li-Yueh HsuLi-Yueh Hsu
Li-Yueh Hsu
HCHannah M. Conn
Hannah M. Conn
SWSusanne Winkler
Susanne Winkler
AGAnders M. Greve
Anders M. Greve
AAAndrew E. Arai
Andrew E. Arai
Dark rim artifacts in first-pass cardiovascular magnetic resonance (CMR) perfusion images can mimic perfusion defects and affect diagnostic accuracy for coronary artery disease (CAD). We evaluated whether quantitative myocardial blood flow (MBF) can differentiate dark rim artifacts from true perfusion defects in CMR perfusion. Regadenoson perfusion CMR was performed at 1.5 T in 76 patients. Significant CAD was defined by quantitative invasive coronary angiography (QCA) ≥ 50% diameter stenosis. Non-significant CAD (NonCAD) was defined as stenosis by QCA < 50% diameter stenosis or computed tomographic coronary angiography (CTA) < 30% in all major epicardial arteries. Dark rim artifacts had study specific and guideline-based definitions for comparison purposes. MBF was quantified at the pixel-level and sector-level. In a NonCAD subgroup with dark rim artifacts, stress MBF was lower in the subendocardial than midmyocardial and epicardial layers (2.17 ± 0.61 vs. 3.06 ± 0.75 vs. 3.24 ± 0.80 mL/min/g, both p < 0.001) and was also 30% lower than in remote regions (2.17 ± 0.61 vs. 2.83 ± 0.67 mL/min/g, p < 0.001). However, subendocardial stress MBF in dark rim artifacts was 37–56% higher than in true perfusion defects (2.17 ± 0.61 vs. 0.95 ± 0.43 mL/min/g, p < 0.001). Absolute stress MBF differentiated CAD from NonCAD with an accuracy ranging from 86 to 89% (all p < 0.001) using pixel-level analyses. Similar results were seen at a sector level. Quantitative stress MBF is lower in dark rim artifacts than remote myocardium but significantly higher than in true perfusion defects. If confirmed in larger series, this approach may aid the interpretation of clinical stress perfusion exams. ClinicalTrials.gov Identifier: NCT00027170 ; first posted 11/28/2001; updated 11/27/2017.